Outlook For AstraZeneca/AtheroGenics’ Candidate May Sink On ARISE Trial Results
This article was originally published in The Pink Sheet Daily
Executive Summary
A Phase III clinical study evaluating the atherosclerosis candidate failed to meet its primary endpoint.